GRANULOTsITARNYE KOLONIESTIMULIRUYuShchIE FAKTORY: SKhODSTVO I RAZLIChIYa


Cite item

Full Text

Abstract

Проведение химиотерапии длительное время ограничивалось ее гематологической токсичностью. Применение гемопоэтических ростовых факторов, в частности гранулоцитарного колониестимулирующего фактора (Г-КСФ), позволило увеличить дозы цитотоксических препаратов и повысить эффективность химиотерапии. Представлены результаты исследований, посвященных изучению свойств и эффективности препаратов Г-КСФ ленограстима и филграстима, являющихся соответственно гликозилированной и негликозилированной формами Г-КСФ. Проведенные клинические исследования продемонстрировали значимость гликозилирования как для эффективности, так и для качества ответа на препарат, что подтверждают и отчасти объясняют преимущества ленограстима (Граноцита) перед филграстимом.

Full Text

Restricted Access

About the authors

S. V Semochkin

References

  1. Bodey G.P, Buckley Y, Sathe Y.S, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia, Ann Intern Med 1966;64:328-40.
  2. Гершанович М.Л. Осложнения при химио- и гормонотерапии злокачественных опухолей. М., 1982.
  3. Klastersky J. Current attitudes for therapy for febrile neutropenia with. Consideration to cost-effectiveness. Curr Opinion Oncol 1998;10:284-90.
  4. Lopez A, et al. Blood 2006;108:475b, abstr. 5512.
  5. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24.
  6. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991;325:164-70.
  7. Souza L.M, Воопе Т.С, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232:61-65.
  8. Oh-Eda M, Hasegawa M, Hattori К, et al. 0-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 1990;265:11432-35.
  9. Ono M. Physicochemical and biochemical characteristics of gly-cosylated recombinant human granulocyte colony-stimulating factor (lenograstim). Eur J Cancer 1994; 30A(Suppl. 3):7-11.
  10. Wang С, Eufemi M, Turano C, et al. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 1996;35: 7299-07.
  11. Arakawa T, Prestrelski S.J, Narhi L.O, et al. Cysteine 17 of recombinant human granulocyte colony-stimulating factor is partially solvent-exposed. J Protein Chem 1993; 12:525-31.
  12. Nissen С. Glycosylation of recombinant human granulocyte colony-stimulating factor: implications for stability and potency. Eur J Cancer 1994;30A(Suppl. 3):12-14.
  13. Oh-Eda M, Hasegawa M, Hattori К, et al. 0-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 1990;265:11432-35.
  14. Ono M. Physicochemical and biochemical characteristics of gly-cosylated recombinant human granulocyte colony-stimulating factor (lenograstim). Eur J Cancer 1994; 30A(Suppl. 3):7-11.
  15. Gisselbrecht С, Haioun C, et al. Placebo -controlled phase III study of Lenograstim (glycosylated recombinant human granulocyte coloni - stimulating factor) in aggressive non - Hodgkin's lyphoma factor factor influencing chemotherapy administration. Leuk Lymphoma 1997;25(3-4):289-300.
  16. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim Prevents Morbidity From Intensive Induction Chemotherapy in the Treatment of Inflammatory Breast Cancer. J Clin Oncol 1995;13(7):1564-71.
  17. Nissen C, Carbonare D, Moser Y. In vitro comparison of the biological potency of glycosylated versus non-glycosylated rG-CSF. Drug Invest 1994;7:346-52.
  18. Venditti A, Battaglia A, Del Poeta G, et al. Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods. Bone Marrow Transplant 1999;24:1019-2 7.
  19. Fourcade M. Human recombinant granulocyte colony stimulating factors: glycosylation makes the difference. La Presse Medicate 1997;26:1460-62.
  20. Watts M.J, Sullivan A.M, Jamieson E, et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor, an analysis of progenitorcell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. Clin Oncol 1997;15:535-46.
  21. Linch D. Activity in clinical settings: comparison of PBPC mobilization with different rG-CSFs in patients with lymphoma. Int J Hematol 1996;64(Suppl. 2):29.
  22. Hoglund M, Smedmyr B, Totterman T.H, et al. Mobilization of CD34+ cells by glycosylated and non-glycosylated G-CSF in healthy volunteers: a comparative study. Eur J Haematol 1997;59:177-83.
  23. Hoglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) - what is the difference? Meet Oncol 1998;15: 229-33.
  24. Ataergin S, Arpaci F, et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: A randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 2008;83(8):644-48.
  25. Aviles A, Guzman R, Garcia E.L, et al. Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs 1996;7(4):392-97.
  26. Garcia-Carbonero R, Mayordomo J.I, Tornamira M.V, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial. J Natl Cancer Inst 2001;93:31 -38.
  27. Clark O.A, Lyman G.H, Castro A.A, et al: Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A metaanalysis of randomized controlled trials. J Clin Oncol 2005;23:4198-214.
  28. Kitagawa S, You A, Souza L.M, et al. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by chemotactic peptide. Biochem Biophys Res Commun 1987;144:1143-46.
  29. Yong K.L, Linch D.C. Differential effects of granulocyte- and granulocyte-macrophage colony-stimulating factors (G- and GM-CSF) on neutrophil adhesion in vitro and in vivo. Eur J Haematol 1992;49:251-59.
  30. Weisbart R.H, Kacena A, Schuh A, et al. GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 1988;332:647-48.
  31. Spertini O, Kansas G.S, Munro J.M, et al. Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. Nature 1991; 349:691-94.
  32. Liles W.C, Rodger E.R, Dale D.C. Differential regulation of human neutrophil surface expression of CD14, CD11b, CD18, and L-selectin following the administration of G-CSF in vivo and in vitro. Clin Res 1994;42:304A.
  33. Ohsaka A, Saionji K, Sato N, et al. Granulocyte-colony stimulating factor down-regulates the surface expression of the human leukocyte adhesion molecule-1 on human neutrophils in vitro and in vivo. Br J Haematol 1993;84:574-80.
  34. Nathan C.F. Respiratory burst in adherent human neutrophils: Triggering by colony-stimulating factors CSF-GM and CSF-F. Blood 1989;73:301-06.
  35. Valerius T, Repp R, de Wit T.P.M, et al. Involvement of the high-affinity receptor for IgG (FcgR1; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 1993;82:931-39.
  36. Yamamoto Y, Klein T.W, Friedman H, et al. Granulocyte colony-stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunol Med Microbiol 1993;7:15-22.
  37. Carulli Gi, Mattii L, et al. Actin polymerization in neutrophils from donors of peripheral blood stem cells: Divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor. Am J Hematology 2006; 81 (Is 5):318-323.
  38. Ribeiro D, Veldwijk M.R, Benner A, et al. Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion 2007;47(6):969-80.
  39. Liliu H, Le Pen C. Evaluation of treatment costs with recombinant human granulocyte colony stimulating factors in mobilization of stem cells. J Pharm Clin 1999;18:277-81.
  40. Debrix I, Ait Ben Ali S, Lotz J.P, et al. Economic evaluation of use of two granulocytecolony-stimulating factors in patients treated intensive chemotherapy. Eur Hosp Pharm 1999;5:24-28.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies